来源:药渡撰文:Pharmadeep编辑:活力哈哈3月21日,跨国药企礼来(Eli Lilly)宣布在印度推出其重磅糖尿病及减肥药物Mounjaro(替尔泊肽注射液),成为首家进军这一全球人口最多市场的GLP-1类减肥药巨头。此举不仅标志着印度肥胖治疗领域的商业化提速,更让礼来在与诺和诺德(Novo Nordisk)的全球竞争中占得先机。然而,高昂的定价与本土仿制药的潜在威胁,也让这场“抢滩战”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.